{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T19:39:23Z","timestamp":1770665963982,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,6,7]],"date-time":"2014-06-07T00:00:00Z","timestamp":1402099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s40618-014-0103-8","type":"journal-article","created":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T10:32:23Z","timestamp":1402050743000},"page":"757-764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and\/or oral contraceptives in polycystic ovary syndrome"],"prefix":"10.1007","volume":"37","author":[{"given":"Dorte","family":"Glintborg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"Mumm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magda Lambaa","family":"Altinok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rn","family":"Richelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Meldgaard","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,7]]},"reference":[{"key":"103_CR1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/09513590903247873","volume":"4","author":"D Glintborg","year":"2010","unstructured":"Glintborg D, Andersen M (2010) An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol 4:281\u2013296","journal-title":"Gynecol Endocrinol"},{"key":"103_CR2","doi-asserted-by":"crossref","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 1:19\u201325","DOI":"10.1016\/j.fertnstert.2003.10.004"},{"key":"103_CR3","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2007-1549","volume":"12","author":"KE Salley","year":"2007","unstructured":"Salley KE, Wickham EP, Cheang KI et al (2007) Position statement: glucose intolerance in polycystic ovary syndrome A position statement of the androgen excess Society. J Clin Endocrinol Metab 12:4546\u20134556","journal-title":"J Clin Endocrinol Metab"},{"issue":"Pt 1","key":"103_CR4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/0029-7844(95)00250-U","volume":"4","author":"T Douchi","year":"1995","unstructured":"Douchi T, Ijuin H, Nakamura S et al (1995) Body fat distribution in women with polycystic ovary syndrome. Obstet Gynecol 4(Pt 1):516\u2013519","journal-title":"Obstet Gynecol"},{"key":"103_CR5","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/humrep\/16.6.1255","volume":"6","author":"S Kirchengast","year":"2001","unstructured":"Kirchengast S, Huber J (2001) Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 6:1255\u20131260","journal-title":"Hum Reprod"},{"key":"103_CR6","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","volume":"9","author":"P Libby","year":"2002","unstructured":"Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 9:1135\u20131143","journal-title":"Circulation"},{"key":"103_CR7","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","volume":"9468","author":"RH Eckel","year":"2005","unstructured":"Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 9468:1415\u20131428","journal-title":"Lancet"},{"key":"103_CR8","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1007\/s00125-003-1228-z","volume":"12","author":"M Fasshauer","year":"2003","unstructured":"Fasshauer M, Paschke R (2003) Regulation of adipocytokines and insulin resistance. Diabetologia 12:1594\u20131603","journal-title":"Diabetologia"},{"key":"103_CR9","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","volume":"12","author":"SP Weisberg","year":"2003","unstructured":"Weisberg SP, McCann D, Desai M et al (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 12:1796\u20131808","journal-title":"J Clin Invest"},{"key":"103_CR10","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1210\/jc.2004-1696","volume":"4","author":"JM Bruun","year":"2005","unstructured":"Bruun JM, Lihn AS, Pedersen SB, Richelsen B (2005) Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 4:2282\u20132289","journal-title":"J Clin Endocrinol Metab"},{"key":"103_CR11","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1210\/jc.2004-0436","volume":"10","author":"P Dandona","year":"2004","unstructured":"Dandona P, Aljada A, Ghanim H et al (2004) Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 10:5043\u20135047","journal-title":"J Clin Endocrinol Metab"},{"key":"103_CR12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/eje.0.1480293","volume":"3","author":"JJ Diez","year":"2003","unstructured":"Diez JJ, Iglesias P (2003) The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 3:293\u2013300","journal-title":"Eur J Endocrinol"},{"key":"103_CR13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.2009.976","volume":"2","author":"S Li","year":"2009","unstructured":"Li S, Shin HJ, Ding EL, van Dam RM (2009) Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2:179\u2013188","journal-title":"JAMA"},{"key":"103_CR14","doi-asserted-by":"crossref","first-page":"E745","DOI":"10.1152\/ajpendo.2001.280.5.E745","volume":"5","author":"PA Kern","year":"2001","unstructured":"Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 5:E745\u2013E751","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"103_CR15","doi-asserted-by":"crossref","first-page":"E527","DOI":"10.1152\/ajpendo.00110.2003","volume":"3","author":"JM Bruun","year":"2003","unstructured":"Bruun JM, Lihn AS, Verdich C et al (2003) Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 3:E527\u2013E533","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"103_CR16","doi-asserted-by":"crossref","first-page":"E1070","DOI":"10.1152\/ajpendo.00529.2007","volume":"6","author":"H Sell","year":"2008","unstructured":"Sell H, Eckardt K, Taube A et al (2008) Skeletal muscle insulin resistance induced by adipocyte-conditioned medium: underlying mechanisms and reversibility. Am J Physiol Endocrinol Metab 6:E1070\u2013E1077","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"103_CR17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1530\/eje.1.02207","volume":"2","author":"D Glintborg","year":"2006","unstructured":"Glintborg D, Andersen M, Hagen C et al (2006) Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 2:337\u2013345","journal-title":"Eur J Endocrinol"},{"key":"103_CR18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2265.2007.03015.x","volume":"2","author":"D Glintborg","year":"2008","unstructured":"Glintborg D, Frystyk J, Hojlund K et al (2008) Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2:165\u2013174","journal-title":"Clin Endocrinol (Oxf)"},{"key":"103_CR19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2265.2009.03523.x","volume":"5","author":"D Glintborg","year":"2009","unstructured":"Glintborg D, Andersen M, Richelsen B, Bruun JM (2009) Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1\u03b1 are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Clin Endocrinol (Oxf) 5:652\u2013658","journal-title":"Clin Endocrinol (Oxf)"},{"key":"103_CR20","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","volume":"2","author":"R Azziz","year":"2009","unstructured":"Azziz R, Carmina E, Dewailly D et al (2009) The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2:456\u2013488","journal-title":"Fertil Steril"},{"key":"103_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1365-2796.1996.364690000.x","volume":"2","author":"P Bjorntorp","year":"1996","unstructured":"Bjorntorp P (1996) The android woman\u2013\u2013a risky condition. J Intern Med 2:105\u2013110","journal-title":"J Intern Med"},{"key":"103_CR22","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1210\/jc.2007-2429","volume":"4","author":"M Cosma","year":"2008","unstructured":"Cosma M, Swiglo BA, Flynn DN et al (2008) Clinical review: insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 4:1135\u20131142","journal-title":"J Clin Endocrinol Metab"},{"key":"103_CR23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.mce.2012.10.029","volume":"1\u20132","author":"GW Bates","year":"2013","unstructured":"Bates GW, Legro RS (2013) Longterm management of Polycystic Ovarian Syndrome (PCOS). Mol Cell Endocrinol 1\u20132:91\u201397","journal-title":"Mol Cell Endocrinol"},{"key":"103_CR24","first-page":"59","volume":"1","author":"P Ravn","year":"2013","unstructured":"Ravn P, Haugen AG, Glintborg D (2013) Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss. Minerva Endocrinol 1:59\u201376","journal-title":"Minerva Endocrinol"},{"key":"103_CR25","first-page":"CD005552","volume":"1","author":"B Shrestha","year":"2007","unstructured":"Shrestha B, Eden J, Sjoblom P, Johnson N (2007) Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 1:CD005552","journal-title":"Cochrane Database Syst Rev"},{"key":"103_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2008-0030","volume":"1","author":"S Palomba","year":"2009","unstructured":"Palomba S, Falbo A, Zullo F, Orio F Jr (2009) Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 1:1\u201350","journal-title":"Endocr Rev"},{"key":"103_CR27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/humrep\/deq301","volume":"1","author":"IJ Halperin","year":"2011","unstructured":"Halperin IJ, Kumar SS, Stroup DF, Laredo SE (2011) The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. Hum Reprod 1:191\u2013201","journal-title":"Hum Reprod"},{"key":"103_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S37559","volume":"6","author":"SM Sirmans","year":"2013","unstructured":"Sirmans SM, Pate KA (2013) Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 6:1\u201313","journal-title":"Clin Epidemiol"},{"key":"103_CR29","doi-asserted-by":"crossref","unstructured":"Glintborg D, Altinok ML, Mumm H, et al (2014) Body composition is improved during 12\u00a0months treatment with metformin alone or combined with oral contraceptives compared to treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab, jc20141135","DOI":"10.1210\/jc.2014-1135"},{"key":"103_CR30","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.fertnstert.2004.06.040","volume":"6","author":"D Glintborg","year":"2004","unstructured":"Glintborg D, Henriksen JE, Andersen M et al (2004) Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. Fertil Steril 6:1570\u20131579","journal-title":"Fertil Steril"},{"key":"103_CR31","first-page":"3161","volume":"9","author":"LC Morin-Papunen","year":"2000","unstructured":"Morin-Papunen LC, Vauhkonen I, Koivunen RM et al (2000) Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 9:3161\u20133168","journal-title":"J Clin Endocrinol Metab"},{"key":"103_CR32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2002-020997","volume":"1","author":"L Morin-Papunen","year":"2003","unstructured":"Morin-Papunen L, Vauhkonen I, Koivunen R et al (2003) Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 1:148\u2013156","journal-title":"J Clin Endocrinol Metab"},{"key":"103_CR33","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2265.2005.02280.x","volume":"6","author":"D Glintborg","year":"2005","unstructured":"Glintborg D, Andersen M, Hagen C, Hermann AP (2005) Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutism. Clin Endocrinol (Oxf) 6:683\u2013691","journal-title":"Clin Endocrinol (Oxf)"},{"key":"103_CR34","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1210\/jc.2006-1847","volume":"7","author":"TL Nielsen","year":"2007","unstructured":"Nielsen TL, Hagen C, Wraae K et al (2007) Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. J Clin Endocrinol Metab 7:2696\u20132705","journal-title":"J Clin Endocrinol Metab"},{"key":"103_CR35","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.metabol.2013.07.004","volume":"11","author":"TP Ciaraldi","year":"2013","unstructured":"Ciaraldi TP, Aroda V, Mudaliar SR, Henry RR (2013) Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. Metabolism 11:1587\u20131596","journal-title":"Metabolism"},{"key":"103_CR36","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.fertnstert.2010.01.057","volume":"6","author":"B Trolle","year":"2010","unstructured":"Trolle B, Lauszus FF, Frystyk J, Flyvbjerg A (2010) Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study. Fertil Steril 6:2234\u20132238","journal-title":"Fertil Steril"},{"key":"103_CR37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1530\/EJE-07-0721","volume":"2","author":"EL Madsen","year":"2008","unstructured":"Madsen EL, Rissanen A, Bruun JM et al (2008) Weight loss larger than 10\u00a0% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2:179\u2013187","journal-title":"Eur J Endocrinol"},{"key":"103_CR38","doi-asserted-by":"crossref","unstructured":"Herder C, Peltonen M, Svensson PA, et al (2014) Adiponectin and bariatric surgery: associations with diabetes and cardiovascular disease in the Swedish obese subjects study. Diabetes Care","DOI":"10.2337\/dc13-1362"},{"key":"103_CR39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1467-789X.2012.01053.x","volume":"2","author":"SS Lim","year":"2013","unstructured":"Lim SS, Norman RJ, Davies MJ, Moran LJ (2013) The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev 2:95\u2013109","journal-title":"Obes Rev"},{"key":"103_CR40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.contraception.2010.02.009","volume":"2","author":"A Kriplani","year":"2010","unstructured":"Kriplani A, Periyasamy AJ, Agarwal N et al (2010) Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception 2:139\u2013146","journal-title":"Contraception"},{"key":"103_CR41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/oby.2008.491","volume":"1","author":"M Luque-Ramirez","year":"2009","unstructured":"Luque-Ramirez M, Alvarez-Blasco F, Escobar-Morreale HF (2009) Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients. Obesity (Silver Spring) 1:3\u20139","journal-title":"Obesity (Silver Spring)"},{"key":"103_CR42","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1210\/jc.2013-2374","volume":"12","author":"JP Domecq","year":"2013","unstructured":"Domecq JP, Prutsky G, Mullan RJ et al (2013) Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab 12:4646\u20134654","journal-title":"J Clin Endocrinol Metab"},{"key":"103_CR43","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.fertnstert.2010.11.036","volume":"3","author":"HF Escobar-Morreale","year":"2011","unstructured":"Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F (2011) Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 3:1048\u20131058","journal-title":"Fertil Steril"},{"key":"103_CR44","first-page":"118","volume":"2","author":"JA Dardzinska","year":"2014","unstructured":"Dardzinska JA, Rachon D, Kuligowska-Jakubowska M et al (2014) Effects of metformin or an oral contraceptive containing cyproterone acetate on serum c-reactive protein, interleukin-6 and soluble vascular cell adhesion molecule-1 concentrations in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2:118\u2013125","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"103_CR45","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1210\/jc.2013-2385","volume":"12","author":"JP Domecq","year":"2013","unstructured":"Domecq JP, Prutsky G, Mullan RJ et al (2013) Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab 12:4655\u20134663","journal-title":"J Clin Endocrinol Metab"},{"key":"103_CR46","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1089\/jwh.2011.3116","volume":"6","author":"NW Karjane","year":"2012","unstructured":"Karjane NW, Cheang KI, Mandolesi GA, Stovall DW (2012) Persistence with oral contraceptive pills versus metformin in women with polycystic ovary syndrome. J Womens Health (Larchmt) 6:690\u2013694","journal-title":"J Womens Health (Larchmt)"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-014-0103-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-014-0103-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-014-0103-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T11:02:24Z","timestamp":1716807744000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-014-0103-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,7]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["103"],"URL":"https:\/\/doi.org\/10.1007\/s40618-014-0103-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,7]]}}}